Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies
Hillen, Heinz × Barghorn, Stefan Striebinger, Andreas Labkovsky, Boris Müller, Reinhold Nimmrich, Volker Nolte, Marc W Perez-Cruz, Claudia van der Auwera, Ingrid Van Leuven, Freddy van Gaalen, Marcel Bespalov, Anton Y Schoemaker, Hans Sullivan, James P Ebert, Ulrich #
The Society for Neuroscience
Journal of Neuroscience vol:30 issue:31 pages:10369-79
Oligomers of the beta-amyloid (Abeta) peptide have been indicated in early neuropathologic changes in Alzheimer's disease. Here, we present a synthetic Abeta(20-42) oligomer (named globulomer) with a different conformation to monomeric and fibrillar Abeta peptide, enabling the generation of highly Abeta oligomer-specific monoclonal antibodies. The globulomer-derived antibodies specifically detect oligomeric but not monomeric or fibrillar Abeta in various Abeta preparations. The globulomer-specific antibody A-887755 was able to prevent Abeta oligomer binding and dynamin cleavage in primary hippocampal neurons and to reverse globulomer-induced reduced synaptic transmission. In amyloid precursor protein (APP) transgenic mice, vaccination with Abeta globulomer and treatment with A-887755 improved novel object recognition. The cognitive improvement is likely attributable to reversing a deficit in hippocampal synaptic spine density in APP transgenic mice as observed after treatment with A-887755. Our findings demonstrate that selective reduction of Abeta oligomers by immunotherapy is sufficient to normalize cognitive behavior and synaptic deficits in APP transgenic mice.